Silvia Buonamici

Silvia brings more than 15 years of drug discovery and translational research experience to Remix. She joins from Monte Rosa Therapeutics where she served as Senior Vice President focusing on discovering molecular glue degraders for oncology and beyond. Silvia held positions of increasing responsibility at the Novartis Institute of Biomedical Research and H3 Biomedicine where she led the discovery and development of three small molecules: the smoothened antagonist, LDE225 (Sonidegib), the allosteric Bcr-Abl inhibitor, ABL001 (Asciminib) and the splice modulator, H3B-8800. Afterwards, she helped build several companies at Third Rock Ventures and Atlas Venture before joining Monte Rosa Tx.

Silvia received her Ph.D. from the University of Bologna in Applied Genetics with a focus on studying the biology of multiple myeloma, acute and chronic myeloid leukemias, after which she conducted postdoctoral studies at the University of Illinois at Chicago and the University of Chicago/New York University on a variety of oncology-centric projects.